Tredegar Corporation
New York Stock ExchangeRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Tredegar Corporation manufactures custom aluminum extrusions and surface protection films. Aluminum Extrusions produces standard and custom extrusions for the North American building and construction, automotive, and specialty end-use markets, including structural components, automotive parts, and consumer durables; Surface Protection, through Tredegar Surface Protection, manufactures high-performance masking films that protect optical films and specialty substrates for LCD and OLED displays in the global electronics industry, as well as automotive, packaging, and other specialty applications, featuring clean room production, customizable treatments, and technologies that maximize manufacturing yields and ensure quality. The company operates manufacturing facilities in North America and Asia, employs approximately 1,500 people, and maintains headquarters in North Chesterfield, Virginia. Tredegar originated as a 1988 spin-off from Ethyl Corporation. In 2024, Tredegar completed the sale of its flexible packaging films business, Terphane, to Oben Group for approximately $116 million in base consideration, streamlining operations to focus on aluminum extrusions and surface protection films; Tredegar Surface Protection also launched Obsidian Automotive Protective Films, expanding its masking solutions for automotive surface protection.
Tredegar Q2 Earnings Rise Y/Y on Aluminum Extrusions Gains
Tredegar (NYSE:TG) Share Price Crosses Above 200 Day Moving Average – Here’s Why
Tredegar Reports Second Quarter 2026 Results
Tredegar Plans to Release Second Quarter 2026 Financial Results on August 7, 2026
Tredegar Announces the Retirement of Frasier W. Brickhouse II, Chief Financial Officer, Treasurer and Vice President, Effective September 1, 2026
Arrowhead Pharmaceuticals Reports Topline Results from Phase 3 SHASTA-3 and SHASTA-4 Studies of Plozasiran in Patients with Severe Hypertriglyceridemia
TRYNGOLZA® (olezarsen) approved by the FDA as the first and only treatment to reduce triglycerides and the risk of acute pancreatitis in patients with severe hypertriglyceridemia (sHTG)
Trifecta Gold Increases Private Placement
Grafton Group Sets 2030 Growth Targets as Cash Flow and Acquisitions Take Center Stage
Tredegar Announces Bonnell Aluminum Leadership Changes
Tredegar Announces Director Transitions
Tredegar Corporation Announces Susan Sweeney Joins Company as Vice President and Chief Human Resources Officer
Arrowhead Pharmaceuticals Presents New Positive Clinical Cardiometabolic Data at the 94th European Atherosclerosis Society (EAS) Congress
TG Stock Down 20% Despite Q1 Earnings Jump Y/Y on Pricing Gains
Tredegar Reports First Quarter 2026 Results
Tredegar's Q4 Earnings Soar Y/Y on Aluminum Extrusions Strength
Tredegar Reports Fourth Quarter and Full Year 2025 Results
Tredegar Plans to Release Fourth Quarter 2025 Financial Results on March 11, 2026
Tredegar Appoints David Parks to Board of Directors
William Gottwald Sells 24,823 Shares of Tredegar (NYSE:TG) Stock